<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9</volume><submitter>Gu L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Although there have been several studies related to serum fibroblast growth factor 21 (FGF21) levels and acute myocardial infarction, the value of serum FGF21 levels in ST-segment elevation myocardial infarction (STEMI) patients after emergency percutaneous coronary intervention (PCI) has not been previously investigated.&lt;h4>Methods&lt;/h4>A total of 348 STEMI patients who underwent emergency PCI were enrolled from January 2016 to December 2018. The primary endpoint was the occurrence of major adverse cardiovascular events (MACEs), with a median follow-up of 24 months. Eighty patients with stable angina (SA) who underwent selective PCI served as the control group. Serum FGF21 levels were measured by ELISA.&lt;h4>Results&lt;/h4>Serum FGF21 levels were significantly higher in the S</pubmed_abstract><journal>PeerJ</journal><pagination>e12235</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8487623</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention.</pubmed_title><pmcid>PMC8487623</pmcid><pubmed_authors>Qian H</pubmed_authors><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Jiang W</pubmed_authors><pubmed_authors>Gu L</pubmed_authors><pubmed_authors>Zheng R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention.</name><description>&lt;h4>Background&lt;/h4>Although there have been several studies related to serum fibroblast growth factor 21 (FGF21) levels and acute myocardial infarction, the value of serum FGF21 levels in ST-segment elevation myocardial infarction (STEMI) patients after emergency percutaneous coronary intervention (PCI) has not been previously investigated.&lt;h4>Methods&lt;/h4>A total of 348 STEMI patients who underwent emergency PCI were enrolled from January 2016 to December 2018. The primary endpoint was the occurrence of major adverse cardiovascular events (MACEs), with a median follow-up of 24 months. Eighty patients with stable angina (SA) who underwent selective PCI served as the control group. Serum FGF21 levels were measured by ELISA.&lt;h4>Results&lt;/h4>Serum FGF21 levels were significantly higher in the S</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-04-19T21:35:48.884Z</modification><creation>2025-04-19T21:35:48.884Z</creation></dates><accession>S-EPMC8487623</accession><cross_references><pubmed>34703671</pubmed><doi>10.7717/peerj.12235</doi></cross_references></HashMap>